Update in the Management and Treatment of Adult Asthma for Primary Care Physicians
DOI:
https://doi.org/10.58931/cpct.2023.115Abstract
Asthma is a common illness; estimates are that it affects up to 18% of the global population, with rates increasing every year. Approximately 3.8 million Canadians have asthma, and these patients continue to suffer from inadequately controlled disease as well as exacerbations. Although we have more medication choice than ever, mortality rates in Canada have not declined. Our current pharmacologic strategy has been mostly unchanged for years; it starts with an anti-inflammatory medication, usually an inhaled corticosteroid (ICS) to treat the type 2 (T2) inflammation that is most common. When an ICS provides inadequate control, therapy is often stepped up to include an ICS/long-acting beta-agonist (LABA) combination and even additional therapies like leukotriene receptor antagonists or long-acting muscarinic agents (LAMAs). As patients with uncontrolled asthma are at risk for deleterious outcomes, controlling the disease and preventing exacerbations should be the goal for all patients.
References
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. GINA. 2022 May 3. http://www.ginasthma.org/
Asher MI, García-Marcos L, Pearce NE, Strachan DP. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094. doi:10.1183/13993003.02094-2020 DOI: https://doi.org/10.1183/13993003.02094-2020
Asthma Canada. Annual asthma survey report: a snapshot of asthma in Canada. 2021 Nov [accessed 2022 Dec 26]. https://asthma.ca/wp-content/uploads/2021/11/2021-Annual-Asthma-Survey-Report-3.pdf
Caminati M, Vaia R, Furci F, Guarnieri G, Senna G. Uncontrolled asthma: unmet needs in the management of patients. J Asthma Allergy. 2021;14:457-66. doi:10.2147/JAA.S260604 DOI: https://doi.org/10.2147/JAA.S260604
Yang CL, Hicks EA, Mitchell P, Reisman J, Podgers D, Hayward KM, Waite M, Ramsey CD. 2021 Canadian Thoracic Society guideline – A focused update on the management of very mild and mild asthma. Can J Respir Crit Care Sleep Med. 2021;5(4):205–45. doi:10.1080/24745332.2021.1877043 DOI: https://doi.org/10.1080/24745332.2021.1877043
Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, Moffat M, Versnel J, Shanahan ER, Hillyer EV, Tunsäter A, Bjermer L. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med. 2008;102(12):1681-93. doi:10.1016/j.rmed.2008.08.003 DOI: https://doi.org/10.1016/j.rmed.2008.08.003
Loewenthal L, Menzies-Gow A. FeNO in asthma. Semin Respir Crit Care Med. 2022;43(5):635-645. doi:10.1055/s-0042-1743290 DOI: https://doi.org/10.1055/s-0042-1743290
Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317:269-79. doi:10.1001/jama.2016.19627 DOI: https://doi.org/10.1001/jama.2016.19627
Walters JA, Hansen E, Mudge P, Johns DP, Walters EH, Wood-Baker R. Barriers to the use of spirometry in general practice. Aust Fam Physician. 2005;34(3):201–3.
Yawn BP, Enright PL, Lemanske RF, Israel E, Pace W, Wollan P, Boushey H. Spirometry can be done in family physicians’ offices and alters clinical decisions in management of asthma and COPD. Chest. 2007;132(4):1162-8. DOI: https://doi.org/10.1378/chest.06-2722
Kaplan A, Stanbrook M. Must family physicians use spirometry in managing asthma patients? YES. Can Fam Physician. 2010;56(2):126-8.
Williams LK, Pladevall M, Hi H , et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114:1288-93. DOI: https://doi.org/10.1016/j.jaci.2004.09.028
Bender B. Physician-patient communication as a tool that can change adherence. Ann Allergy Asthma Immunol. 2009;103(1):1-2. DOI: https://doi.org/10.1016/S1081-1206(10)60134-2
Bosnic-Anticevich S. Inhaler technique in asthma: how doesit relate to patients’ preferences and attitudes toward their inhalers? J Aerosol Med Pulm Drug Deliv. 2017;30(1):42-52. doi:10.1089/jamp.2016.1287 DOI: https://doi.org/10.1089/jamp.2016.1287
Usmani O, Hickey A, Guranlioglu D, Rawson K, Stepanovic N, Siddiqui S, Dhand R. The impact of inhaler device regimen in patients with asthma or COPD. J Allergy Clin Immunol: In Practice. 2021;9(8):3033–40. doi:10.1016/j.jaip.2021.04.024 DOI: https://doi.org/10.1016/j.jaip.2021.04.024
Kaplan A, Price D. Matching inhaler devices with patients: the role of the primary care physician. Can Respir J. 2018;2018:9473051. doi:10.1155/2018/9473051 DOI: https://doi.org/10.1155/2018/9473051
McIvor RA, Devlin HM, Kaplan A. Optimizing the Delivery of Inhaled Medication for Respiratory Patients: The Role of Valved Holding Chambers. Can Respir J. 2018 Apr 4;2018:5076259. doi: 10.1155/2018/5076259 DOI: https://doi.org/10.1155/2018/5076259
Kaplan A, Kim J. Asthma exacerbations and glucagon-like peptide-1 receptor agonists: a review of the current evidence. Pulm Ther. 2022;8:343–56. doi:10.1007/s41030-022-00203 DOI: https://doi.org/10.1007/s41030-022-00203-x
Boulet LP. Asthma and obesity. Clin Exp Allergy. 2013;43(1):8-21. doi:10.1111/j.1365-2222.2012.04040.x DOI: https://doi.org/10.1111/j.1365-2222.2012.04040.x
Kaplan A. SABA over-reliance; time for a change. J Lung Pulm Respir Res. 2019;6(4):101-2. doi:10.15406/jlprr.2019.06.00217 DOI: https://doi.org/10.15406/jlprr.2019.06.00217
Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2022;59(1):2102730. doi:10.1183/13993003.02730-2021 DOI: https://doi.org/10.1183/13993003.02730-2021
Rhee H, Belyea MJ, Brasch J. Family support and asthma outcomes in adolescents: barriers to adherence as a mediator. J Adolesc Health. 2010;47(5):472-8. doi:10.1016/j.jadohealth.2010.03.009 DOI: https://doi.org/10.1016/j.jadohealth.2010.03.009
Gibson PG, Powell H, Wilson A, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews. 1998;(4):CD001117.
Hall C, Nici L, Sood S, ZuWallack R, Castro M. Nonpharmacologic Therapy for Severe Persistent Asthma. J Allergy Clin Immunol Pract. 2017;5(4):928-35. doi:10.1016/j.jaip.2017.04.030 DOI: https://doi.org/10.1016/j.jaip.2017.04.030
Vathenen AS, Knox AJ, Wisniewski A, et al. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis. 1991;143(6):1317-21. doi:10.1164/ajrccm/143.6.1317 DOI: https://doi.org/10.1164/ajrccm/143.6.1317
Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med. 2004;170(8):836-44. doi:10.1164/rccm.200401-033OC DOI: https://doi.org/10.1164/rccm.200401-033OC
Nelson HS, Weiss ST, Bleeker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26. DOI: https://doi.org/10.1378/chest.129.1.15
Vogelberg C, Goldstein S, Graham L, Kaplan A, de la Hoz A, Hamelmann E. A comparison of tiotropium, long-acting β2-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma. Respir Res. 2020;21:19 doi:10.1186/s12931-020-1282-9 DOI: https://doi.org/10.1186/s12931-020-1282-9
Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database of Systematic Reviews. 2010;(8):CD001186. doi:10.1002/14651858.CD001186.pub2 DOI: https://doi.org/10.1002/14651858.CD001186.pub2
Kaplan A, Chang KL. Tiotropium in asthma – perspectives for the primary care physician. Postgrad Med. 2021;133(5):552–64. doi:10.1080/00325481.2020.1816329 DOI: https://doi.org/10.1080/00325481.2020.1816329
Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, Buhl R, Cruz AA, Fleming L, Inoue H, et al. GINA 2019: a fundamental change in asthma management. Eur Respir J. 2019;53(6):1901046. doi:10.1183/13993003.01046-2019 DOI: https://doi.org/10.1183/13993003.01046-2019
Kaplan A. The myth of mild: severe exacerbations in mild asthma: an underappreciated, but preventable problem. Adv Ther. 2021;38(3):1369–81. doi:10.1007/s12325-020-01598-2 DOI: https://doi.org/10.1007/s12325-020-01598-2
Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, Fabbri LM; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med. 2007;356(20):2040–52. doi:10.1056/NEJMoa063861 DOI: https://doi.org/10.1056/NEJMoa063861
Chipps BE, Albers FC, Reilly L, et al. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. BMJ Open Respir Res. 2021;8:e001077. doi:10.1136/bmjresp-2021-001077 DOI: https://doi.org/10.1136/bmjresp-2021-001077
Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–207. doi:10.1056/NEJMoa1208606 DOI: https://doi.org/10.1056/NEJMoa1208606
Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170:106021. doi:10.1016/j.rmed.2020.106021 DOI: https://doi.org/10.1016/j.rmed.2020.106021
Busse WW, Abbott CB, Germain G, Laliberté F, MacKnight SD, Jung Y, Duh MS, Averell CM. Adherence and persistence to single-inhaler versus multiple-inhaler triple therapy for asthma management. J Allergy Clin Immunol Pract. 2022;10(11):2904-13.e6. doi:10.1016/j.jaip.2022.06.010 DOI: https://doi.org/10.1016/j.jaip.2022.06.010
Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. Eur Respir Rev. 2020;29(155):190151. doi:10.1183/16000617.0151-2019 DOI: https://doi.org/10.1183/16000617.0151-2019
Bleecker ER, Al-Ahmad M, Bjermer L, Caminati M, Canonica GW, Kaplan A, Papadopoulos NG, Roche N, Ryan D, Tohda Y, Yáñez A, Price D. Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group. World Allergy Organ J. 2022;15(12):100726. doi:10.1016/j.waojou.2022.100726 DOI: https://doi.org/10.1016/j.waojou.2022.100726
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73. DOI: https://doi.org/10.1183/09031936.00202013
Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. DOI: https://doi.org/10.1016/j.jaci.2014.08.042
Beekman M, Hales J, Al-Ahmad M, del Olmo R, Tan TL. Breaking the vicious circle—the Asthma Referral Identifier (ReferID) tool. npj Prim Care Respir Med. 2022;32:40. doi:10.1038/s41533-022-00296-6 DOI: https://doi.org/10.1038/s41533-022-00296-6
Published
Versions
- 2023-03-28 (2)
- 2023-03-28 (1)
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian Primary Care Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
